Josee-Lyne Ethier1, Rebecca M Prince1, Eitan Amir2. 1. Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre and Department of Medicine, University of Toronto, 610 University Ave 5-124, Toronto, ON, M5G 2M9, Canada. 2. Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre and Department of Medicine, University of Toronto, 610 University Ave 5-124, Toronto, ON, M5G 2M9, Canada. eitan.amir@uhn.ca.
Abstract
PURPOSE OF REVIEW: Many studies have examined the effects of adjuvant bisphosphonates on long-term breast cancer outcomes. However, results have been inconsistent. Here, we review the evidence for their role in early breast cancer. RECENT FINDINGS: In a recent meta-analysis, no significant decreases in recurrence or breast cancer mortality were observed in the overall population. In postmenopausal women, statistically significant, but modest, reductions in distant recurrence were observed, driven by decreased bone recurrence. This translated to decreased breast cancer mortality. While most individual studies were not performed exclusively in postmenopausal patients and were not adequately powered to detect subgroup effects based on menopausal status, observed effects were highly consistent. Adjuvant bisphosphonates in postmenopausal women should be considered in individual cases of high-risk patients, where the absolute benefit justifies associated risks. There is no evidence supporting their routine use in premenopausal women except in selected patients receiving ovarian function suppression.
PURPOSE OF REVIEW: Many studies have examined the effects of adjuvant bisphosphonates on long-term breast cancer outcomes. However, results have been inconsistent. Here, we review the evidence for their role in early breast cancer. RECENT FINDINGS: In a recent meta-analysis, no significant decreases in recurrence or breast cancer mortality were observed in the overall population. In postmenopausal women, statistically significant, but modest, reductions in distant recurrence were observed, driven by decreased bone recurrence. This translated to decreased breast cancer mortality. While most individual studies were not performed exclusively in postmenopausal patients and were not adequately powered to detect subgroup effects based on menopausal status, observed effects were highly consistent. Adjuvant bisphosphonates in postmenopausal women should be considered in individual cases of high-risk patients, where the absolute benefit justifies associated risks. There is no evidence supporting their routine use in premenopausal women except in selected patients receiving ovarian function suppression.
Entities:
Keywords:
Adjuvant therapy; Bisphosphonate; Bone modifier; Breast cancer; Disease-free survival; Overall survival; Recurrence
Authors: Adam M Brufsky; W Graydon Harker; J Thaddeus Beck; Linda Bosserman; Charles Vogel; Christopher Seidler; Lixian Jin; Ghulam Warsi; Eliza Argonza-Aviles; John Hohneker; Solveig G Ericson; Edith A Perez Journal: Cancer Date: 2011-10-10 Impact factor: 6.860
Authors: Michael Gnant; Brigitte Mlineritsch; Herbert Stoeger; Gero Luschin-Ebengreuth; Dietmar Heck; Christian Menzel; Raimund Jakesz; Michael Seifert; Michael Hubalek; Gunda Pristauz; Thomas Bauernhofer; Holger Eidtmann; Wolfgang Eiermann; Guenther Steger; Werner Kwasny; Peter Dubsky; Gerhard Hochreiner; Ernst-Pius Forsthuber; Christian Fesl; Richard Greil Journal: Lancet Oncol Date: 2011-06-05 Impact factor: 41.316
Authors: R L Theriault; A Lipton; G N Hortobagyi; R Leff; S Glück; J F Stewart; S Costello; I Kennedy; J Simeone; J J Seaman; R D Knight; K Mellars; M Heffernan; D J Reitsma Journal: J Clin Oncol Date: 1999-03 Impact factor: 44.544
Authors: R Coleman; R de Boer; H Eidtmann; A Llombart; N Davidson; P Neven; G von Minckwitz; H P Sleeboom; J Forbes; C Barrios; A Frassoldati; I Campbell; O Paija; N Martin; A Modi; N Bundred Journal: Ann Oncol Date: 2012-10-09 Impact factor: 32.976
Authors: Robert Coleman; David Cameron; David Dodwell; Richard Bell; Caroline Wilson; Emma Rathbone; Maccon Keane; Miguel Gil; Roger Burkinshaw; Robert Grieve; Peter Barrett-Lee; Diana Ritchie; Victoria Liversedge; Samantha Hinsley; Helen Marshall Journal: Lancet Oncol Date: 2014-07-15 Impact factor: 41.316
Authors: Olivia Pagani; Meredith M Regan; Barbara A Walley; Gini F Fleming; Marco Colleoni; István Láng; Henry L Gomez; Carlo Tondini; Harold J Burstein; Edith A Perez; Eva Ciruelos; Vered Stearns; Hervé R Bonnefoi; Silvana Martino; Charles E Geyer; Graziella Pinotti; Fabio Puglisi; Diana Crivellari; Thomas Ruhstaller; Eric P Winer; Manuela Rabaglio-Poretti; Rudolf Maibach; Barbara Ruepp; Anita Giobbie-Hurder; Karen N Price; Jürg Bernhard; Weixiu Luo; Karin Ribi; Giuseppe Viale; Alan S Coates; Richard D Gelber; Aron Goldhirsch; Prudence A Francis Journal: N Engl J Med Date: 2014-06-01 Impact factor: 91.245
Authors: Trevor Powles; Alexander Paterson; Eugene McCloskey; Phil Schein; Bobbi Scheffler; Alwynne Tidy; Sue Ashley; Ian Smith; Lars Ottestad; John Kanis Journal: Breast Cancer Res Date: 2006-03-15 Impact factor: 6.466